Orlando, FL—The ideal treatment in 2017 for patients with newly diagnosed multiple myeloma is a combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone. Bortezomib-based maintenance therapy is particularly relevant in patients with high-risk disease and residual disease, and in the relapsed setting, triplet therapy is preferred over doublet therapy. These are among the key therapeutic points in the current National Comprehensive Cancer Network (NCCN) guideline for the management of multiple myeloma (version 3.2017), said Shaji K. Kumar, MD, Professor of Medicine, Mayo Clinic Cancer Center, Rochester, MN, at the 2017 NCCN annual conference. He discussed the use of current therapies based on the NCCN guidelines.
[ Read More ]